Your Previous Searches:
Recently Visited Pages:
Metals & Mining
In this interview, Dr Jan Schmidt-Brand, CEO of Heidelberg Pharma, provides an overview of the company and what differentiates its ATAC products from other ADC or CAR-Ts on the market. He also shares the company’s key partnerships and pipeline overview, the upcoming catalysts investors should pay attention to, and how the company is funded.
Get access to the very latest content matched to your personal investment style.